StockData
Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc. (HRMY) company profile

HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.11+0.10 (+0.30%)

Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –

About Harmony Biosciences

Pharmaceutical Preparations, SIC 2834

Harmony Biosciences is a commercial-stage neuroscience company focused on developing and commercializing therapies for patients living with rare neurological diseases. Its therapeutic portfolio spans sleep and wake disorders, rare epilepsies, and neurobehavioral conditions. The company's lead commercial product is WAKIX, a selective histamine 3 receptor antagonist/inverse agonist administered once daily for the treatment of excessive daytime sleepiness and cataplexy in adult and pediatric narcolepsy patients. Harmony also advances a clinical pipeline of next-generation pitolisant formulations, orexin receptor agonists, and serotonin receptor agonists. The company sells its commercial therapies to specialty pharmacies and distributors, including Caremark, Accredo Health Group, and PANTHERx Specialty Pharmacy, which supply patients.

The company operates through wholly owned subsidiaries and commercializes its core treatment in the United States, with licensed development and commercialization rights extending to Latin America for certain pipeline candidates. Harmony Biosciences does not own or operate manufacturing, storage, or distribution facilities, relying entirely on contracted third-party suppliers and manufacturers across the United States and Europe. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Harmony Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Harmony Biosciences Holdings, Inc.
Headquarters
Plymouth Meeting, PA
Address
630 W Germantown Pike, Suite 215 19462
Phone
(484) 539-9800
Employees
293, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte& Touche LLP, Philadelphia, PA

Stock & identifiers

Ticker
HRMY
Exchange
Nasdaq
IPO date
Aug 20, 2020
Shares outstanding
58M, Jul 31, 2026
Public float
$1.32B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1802665
CUSIP
413197104
ISIN
US4131971040
FIGI
BBG00WBPG4C2
Share class FIGI
BBG00WBPG548
EIN
82-2279923

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jeffrey M. DaynoPRESIDENT, CEO, Director13,000
Kumar BudurCHIEF MEDICAL OFFICER48,967
Stephen M. MollichellaINT PRINCIAL FINANCIAL OFFICER2,506
Glenn ReicinCHIEF FINANCIAL OFFICER–
Adam H. ZaeskeCHIEF COMMERCIAL OFFICER4,327
Peter AnastasiouCHIEF OPERATING OFFICER–
Sandip KapadiaCHIEF FINANCIAL OFFICER24,521
Andrew SerafinCHIEF STRATEGY OFFICER1,474
Jeffrey DierksCHIEF COMMERCIAL OFFICER500
R. Mark GrafDirector–
Geno J. GermanoDirector–
Linda M. SzyperDirector–
Ron M. PhilipDirector–
Juan A. SabaterDirector29,497
Gary SenderDirector–
Troy A. IgnelziDirector–
Antonio J. GraciasDirector845,336

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$7.90M$4.76M$2.70M$104$120
FY2024
Jeffrey Dayno
$7.15M$7.68M$3.34M$93$103
FY2024
Jeffrey M.Dayno
$7.15M$7.68M$3.34M$93$103
FY2024
John CJacobs
$0$0$3.34M$93$103
FY2023
Jeffrey Dayno
$4.45M$2.91M$3.15M$87$104
FY2023
Jeffrey M.Dayno
$4.45M$2.91M$3.15M$87$104

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Jeffrey M. Dayno, M.D.
President and Chief Executive Officer
$743.60K–$1.98M$4.60M$558.00K$22.42K$7.90M+11%
Sandip Kapadia
EVP and Chief Financial Officer and Chief Administrative Officer
$522.83K–$718.39K$1.69M$248.35K$22.06K$3.20M+4%
Adam Zaeske
EVP and Chief Commercial Officer
$376.92K$200.00K$852.00K$1.87M$189.04K$180.26K$3.66M–
Kumar Budur
EVP and Chief Medical & Scientific Officer
$598.00K–$404.81K$955.57K$299.00K$22.06K$2.28M-60%
Andrew Serafin
EVP, Chief Strategy Officer
$439.21K–$395.30K$932.58K$219.61K$22.59K$2.01M-4%
Jeffrey Dierks
Former EVP and Chief Commercial Officer
$132.26K–$511.24K$1.21M–$497.49K$2.35M-5%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 20, 2020
Offer price
$24.00
Securities offered
5,348,837
Gross proceeds
$128.37M
Exchange
Nasdaq
First trading day
Aug 19, 2020
First-day close
$37.01+54.2%
Lock-up ends (est.)
Feb 15, 2021

“The initial public offering price per share is $24.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 293 full-time employees, 135 dedicated to commercial functions, which includes sales, marketing, market access, commercial operations, and insights, and 103 dedicated to research and development.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?